D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer

Annals of Oncology

Volumn 21, Issue 6, 2009, Pages 1267-1272

  Batschauer, A P B ^a   Figueiredo, C P ^a   Bueno, E C ^a   Ribeiro, M A ^b   Dusse, L M S ^c   Fernandes, A P ^c   Gomes, K B ^c,d   Carvalho, M G ^c  

^a UNIVERSIDADE DO VALE DO ITAJAÍ   (Brazil)

^b Hospital e Maternidade Marieta Konder Bornhausen   (Brazil)

^c Technical College   (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

D dimer; Hormone receptor negative; Hypercoagulability; Operable breast cancer; Prognostic

Indexed keywords

D DIMER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROTEIN P53; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER GRADING; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; BLOOD; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; EVALUATION STUDY; METABOLISM; MIDDLE AGED; MORTALITY; PHYSIOLOGY; SURVIVAL;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77953987382     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp474     Document Type: Article

References (32)

1. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181-187.
2. Rock CL, Flatt SW, Laughlin GA et al. Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 614-620.
3. Ozbas S, Dafydd H, Purushotham AD. Bone marrow micrometastasis in breast cancer. Br J Surg 2003; 90: 290-301.
4. Ciatto S, Cecchini S, Grazzini G et al. Tumor size and prognosis of breast cancer with negative axillary nodes. Neoplasma 1990; 37: 179-184.
5. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
6. Pereira H, Pinder SE, Sibbering DM et al. Pathological prognostic factors in breast cancer. IV: should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995; 27: 219-226.
7. Ariga R, Zarif A, Korasick J et al. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J 2005; 11: 278-280.
8. Lang JE, Mosalpuria K, Cristofanilli M et al. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat 2009; 113: 501-507.
9. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34: 791-808.
10. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
11. Versteeg HH, Schaffner F, Kerver M et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008; 111: 190-199.
12. Warnberg F, Nordgren H, Bergkvist L et al. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer 2001; 85: 869-874.
13. Choi HK, Roh SH, Kim HG et al. Enhanced expression of aromatase in p53-inactivated mammary epithelial cells. Endocr Relat Cancer 2008; 15: 139-147.
14. Teschendorff AE, Miremadi A, Pinder SE et al. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007; 8: R157.
15. Kausch I, Lingnau A, Endl E et al. Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo. Int J Cancer 2003; 105: 710-716.
16. Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996; 2: 167-168.
17. Dirix LY, Salgado R, Weytjens R et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86: 389-395.
18. Byrne GJ, McDowell G, Agarawal R et al. Serum vascular endothelial growth factor in breast cancer. Anticancer Res 2007; 27: 3481-3487.
19. Kilic M, Yoldas O, Keskek M et al. Prognostic value of plasma D-dimer levels in patients with colorectal cancer. Colorectal Dis 2008; 10: 238-241.
20. Linenberger ML, Wittkowsky AK. Thromboembolic complications of malignancy. Part 1: risks. Oncology (Williston Park) 2005; 19: 853-861.
21. Benoy IH, Salgado R, Elst H et al. Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer. Breast Cancer Res 2005; 7: R210-R219.
22. Grondahl-Hansen J, Peters HA, van Putten WL et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995; 1: 1079-1087.
23. Pradhan AD, LaCroix AZ, Langer RD et al. Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women. Circulation 2004; 110: 292-300.
24. Rak J, Yu JL, Luyendyk J et al. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 2006; 66: 10643-10646.
25. Blackwell K, Haroon Z, Broadwater G et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 2000; 18: 600-608.
26. Truong PT, Olivotto IA, Kader HA et al. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2005; 61: 1337-1347.
27. Gulben K, Berberoglu U, Cengiz A et al. Prognostic factors affecting locoregional recurrence in patients with stage IIIB noninflammatory breast cancer. World J Surg 2007; 31: 1724-1730.
28. Rakha EA, El-Sayed ME, Green AR et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32.
29. Askmalm MS, Carstensen J, Nordenskjold B et al. Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients. Acta Oncol 2004; 43: 235-244.
30. Iwaya K, Tsuda H, Fukutomi T et al. Histologic grade and p53 immunoreaction as indicators of early recurrence of node-negative breast cancer. Jpn J Clin Oncol 1997; 27: 6-12.
31. Salgado R, Benoy I, Weytjens R et al. Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. Br J Cancer 2002; 87: 1437-1444.
32. Konecny G, Untch M, Arboleda J et al. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin Cancer Res 2001; 7: 2448-2457.